Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23458725 | 0.94 | SIGMAR1 (0.36) | SIGMAR1KDM4EMEN1LMNAMAPT | |
| SCHEMBL21923938 | 0.92 | KDM4E (0.34) | SIGMAR1KDM4EMEN1LMNAMAPT | |
| SCHEMBL22403530 | 0.92 | MEN1 (0.36) | SIGMAR1KDM4EMEN1LMNAMAPT | |
| SCHEMBL17903136 | 0.91 | MEN1 (0.38) | SIGMAR1KDM4EMEN1LMNAMAPT | |
| SCHEMBL21037606 | 0.91 | SIGMAR1 (0.36) | SIGMAR1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL21559455 | 0.91 | CHRNB4 (0.32) | — | |
| SCHEMBL26001525 | 0.90 | KDM4E (0.36) | SIGMAR1KDM4EMEN1LMNAMAPT | |
| SCHEMBL21037290 | 0.90 | KDM4E (0.36) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL21923889 | 0.90 | MEN1 (0.38) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL23461826 | 0.89 | CA12 (0.34) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019103397-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | 주식회사 두산 | 2019-05-31 | — | — | WO | disclosed |